PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8645994

Sustained decrease of serum total IgE in cardiac transplant recipients.

A W van Toorenenbergen·A H Balk·A M Vermeulen
View original source ↗Export metadata ↓

Abstract

A steady decrease in serum IgE was noted in cardiac transplant recipients receiving a combination of cyclosporin A and prednisolone for immunosuppressive therapy. The average time period for the demonstration of a 50% decrease in serum IgE levels was calculated to be 40 +/- 16 days in 19 patients.

Explore related subjects

CyclosporineDrug Therapy, CombinationHeart TransplantationHumansImmunoglobulin EPrednisoloneTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A W van Toorenenbergen, A H Balk, A M Vermeulen. 1996. Sustained decrease of serum total IgE in cardiac transplant recipients.. https://doi.org/10.1159/000237282

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group.

Within the multicenter European FK506 (tacrolimus) liver study, patients who received transplants for fulminant hepatic failure (FHF) were stratified separately from those having an elective transplant procedure. At 2-year follow-up, in addition to a comparison of the outcome between these two clinical groups, we report the efficacy and safety of tacrolimus primary immunosuppression (n=32) as compared with a cyclosporine-based regimen (n=23) in FHF. The FHF patients experienced more episodes of acute rejection and sepsis with reduced patient and graft survival rates compared with the elective group (e.g., retransplantation rate of 10/44 [22.7%] vs. 47/485 [9.7%], respectively). Among the FHF patients, tacrolimus reduced the actuarial incidence of acute rejection compared with patients treated with cyclosporine, and whereas refractory acute and chronic rejection occurred in four (17.4%) and two patients (8.7%), respectively, treated with cyclosporine, no rejection episodes were recorded in patients receiving tacrolimus. No difference in the actuarial patient or graft survival rates was observed between the two groups. Patients treated with tacrolimus tended to have a lower incidence of infection (pneumonia, 19.0% vs. 26.1%; cytomegalovirus infection, 9.5% vs. 26.1%; and sepsis, 23.8% vs. 39.1%). Corticosteroid dosage requirements were reduced in the tacrolimus-treated group with the cumulative dosage exposure from 20.8% to 37.2% lower on a monthly basis. No significant differences in adverse events attributable to the immunosuppressive drugs were found.

Cyclosporine↗
PubMed1996

Rapamycin inhibits aldolase A expression during human lymphocyte activation.

Rapamycin (RAPA) strongly inhibits lymphocyte activation and proliferation, but does not affect most of the activation-related gene expression at the mRNA level. In order to understand the mechanism of action of RAPA and to gain further insights in lymphocyte signalling which is impaired by RAPA, we screened for RAPA-sensitive genes using differential hybridization. The expression of human aldolase A gene was found to be inducible during T and B cell activation, and the induction was repressed by RAPA at both the mRNA and enzymatic levels. The other two important immunosuppressants, cyclosporin A and FK506, also inhibited the mitogen-induced upregulation. However, none of these three drugs inhibited the constitutive expression. There was no fluctuation of aldolase A expression during the cell cycle, and RAPA failed to block the first cell cycle after synchronization in Jurkat cells. However, the second cycle was hampered by RAPA, and this was correlated with the inhibition of aldolase A expression during this later stage. Since aldolase A is a key enzyme in glycolysis and lymphocytes mainly depend on glycolysis for energy supply, the data from this study suggest that aldolase A might be one of the downstream targets of RAPA. The inhibition of the enzyme upregulation might deprive the cells of additional supply of energy, and prevent the cells from entering an optimal status for proliferation.

Cyclosporine↗